Any feedback?
Information on EC 1.14.11.27 - [histone H3]-dimethyl-L-lysine36 demethylase
for references in articles please use BRENDA:EC1.14.11.27Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.14.11.27 [histone H3]-dimethyl-L-lysine36 demethylaseIUBMB Comments
Requires iron(II). Of the seven potential methylation sites in histones H3 (K4, K9, K27, K36, K79) and H4 (K20, R3) from HeLa cells, the enzyme is specific for Lys36. Lysine residues exist in three methylation states (mono-, di- and trimethylated). The enzyme preferentially demethylates the dimethyl form of Lys36 (K36me2), which is its natural substrate, to form the monomethylated and unmethylated forms of Lys36. It can also demethylate monomethylated (but not the trimethylated) Lys36. cf. EC 1.14.11.69, [histone H3]-trimethyl-L-lysine36 demethylase.
Specify your search results
Word Map
- 1.14.11.27
- demethylases
- chromatin
-
demethylation
-
h3k9me3
-
trimethylation
-
jumonji
- tumorigenesis
- methyltransferases
-
lysine-specific
- heterochromatin
-
tri-methylated
-
tudor
-
chromatin-modifying
- jmjd1a
-
jmjc-domain-containing
- setdb1
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
jmjd2a, kdm4b, kdm2b, kdm4a, kdm2a, kdm4c, lysine demethylase, jmjd5, kdm4d, gasc1, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME 
IUBMB Comments
[histone H3]-N6,N6-dimethyl-L-lysine36,2-oxoglutarate:oxygen oxidoreductase
Requires iron(II). Of the seven potential methylation sites in histones H3 (K4, K9, K27, K36, K79) and H4 (K20, R3) from HeLa cells, the enzyme is specific for Lys36. Lysine residues exist in three methylation states (mono-, di- and trimethylated). The enzyme preferentially demethylates the dimethyl form of Lys36 (K36me2), which is its natural substrate, to form the monomethylated and unmethylated forms of Lys36. It can also demethylate monomethylated (but not the trimethylated) Lys36. cf. EC 1.14.11.69, [histone H3]-trimethyl-L-lysine36 demethylase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY 
55071-98-2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Adenocarcinoma
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
Adenocarcinoma
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
Adenocarcinoma
Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression.
Adenocarcinoma
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma.
Adenocarcinoma
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Adenocarcinoma
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Arthritis, Rheumatoid
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
Ataxia Telangiectasia
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Atherosclerosis
Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL.
Bone Diseases, Metabolic
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Brain Diseases
KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels.
Brain Neoplasms
KDM2B Recruitment of the Polycomb Group Complex, PRC1.1, Requires Cooperation between PCGF1 and BCORL1.
Breast Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Breast Neoplasms
Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
Breast Neoplasms
Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women.
Breast Neoplasms
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
Breast Neoplasms
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
Breast Neoplasms
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Breast Neoplasms
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Breast Neoplasms
FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Breast Neoplasms
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Breast Neoplasms
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Breast Neoplasms
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Breast Neoplasms
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Breast Neoplasms
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Breast Neoplasms
Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.
Breast Neoplasms
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Breast Neoplasms
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
Breast Neoplasms
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Breast Neoplasms
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
Breast Neoplasms
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Breast Neoplasms
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Breast Neoplasms
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Breast Neoplasms
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Breast Neoplasms
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Breast Neoplasms
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Breast Neoplasms
Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer.
Breast Neoplasms
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Breast Neoplasms
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
Breast Neoplasms
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Breast Neoplasms
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Breast Neoplasms
Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription.
Breast Neoplasms
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Breast Neoplasms
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Breast Neoplasms
The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer.
Burkitt Lymphoma
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Carcinogenesis
CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Carcinogenesis
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Carcinogenesis
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
Carcinogenesis
Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.
Carcinogenesis
Histone demethylase KDM2A: Biological functions and clinical values (Review).
Carcinogenesis
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Carcinogenesis
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Carcinogenesis
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Carcinogenesis
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Carcinogenesis
Identification and functional implication of nuclear localization signals in the N-terminal domain of JMJD5.
Carcinogenesis
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
Carcinogenesis
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Carcinogenesis
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
Carcinogenesis
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Carcinogenesis
KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.
Carcinogenesis
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
Carcinogenesis
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
Carcinogenesis
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Carcinogenesis
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
Carcinogenesis
LncRNA LINC01278 accelerates colorectal cancer progression via miR-134-5p/KDM2A axis.
Carcinogenesis
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Carcinogenesis
Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.
Carcinogenesis
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Carcinogenesis
The Emerging Role of Lysine Demethylases in DNA Damage Response: Dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites.
Carcinogenesis
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
Carcinogenesis
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Carcinogenesis
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Carcinogenesis
Wnt-Induced Stabilization of KDM4C Is Required for Wnt/?-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.
Carcinoma
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
Carcinoma
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Carcinoma
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Carcinoma
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Carcinoma
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Carcinoma
Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines.
Carcinoma
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
Carcinoma
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Carcinoma
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Carcinoma
GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation.
Carcinoma
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Carcinoma
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Carcinoma
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Carcinoma
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Carcinoma
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
Carcinoma
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
Carcinoma
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.
Carcinoma
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Carcinoma
Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line.
Carcinoma
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Carcinoma
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Carcinoma in Situ
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Carcinoma, Ductal
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Carcinoma, Hepatocellular
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
Carcinoma, Hepatocellular
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Carcinoma, Hepatocellular
Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A.
Carcinoma, Intraductal, Noninfiltrating
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Carcinoma, Non-Small-Cell Lung
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Carcinoma, Non-Small-Cell Lung
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
Carcinoma, Non-Small-Cell Lung
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
Carcinoma, Non-Small-Cell Lung
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Carcinoma, Non-Small-Cell Lung
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Carcinoma, Ovarian Epithelial
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Carcinoma, Renal Cell
KDM3A is not associated with metastasis and prognosis of breast cancer.
Carcinoma, Squamous Cell
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
Carcinoma, Squamous Cell
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
Carcinoma, Squamous Cell
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Carcinoma, Squamous Cell
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Carcinoma, Squamous Cell
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Carcinoma, Squamous Cell
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Carcinoma, Squamous Cell
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Squamous Cell
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Cardiomegaly
The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes.
Cardiomegaly
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Cardiomyopathy, Hypertrophic
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Colitis
Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction.
Colonic Neoplasms
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin.
Colonic Neoplasms
CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Colonic Neoplasms
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Colonic Neoplasms
Mutation and expression alterations of histone methylation-related NSD2, KDM2B and SETMAR genes in colon cancers.
Colonic Neoplasms
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Colonic Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Colonic Neoplasms
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Colorectal Neoplasms
Activation of TC10-Like Transcription by Lysine Demethylase KDM4B in Colorectal Cancer Cells.
Colorectal Neoplasms
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Colorectal Neoplasms
Histone lysine demethylase 3B (KDM3B) regulates the propagation of autophagy via transcriptional activation of autophagy-related genes.
Colorectal Neoplasms
KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation.
Colorectal Neoplasms
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
Colorectal Neoplasms
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Colorectal Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Colorectal Neoplasms
The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway.
Diabetes Mellitus, Type 1
Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.
Diabetes Mellitus, Type 1
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Endometrial Neoplasms
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Endometrial Neoplasms
KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Epstein-Barr Virus Infections
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Esophageal Neoplasms
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
Esophageal Squamous Cell Carcinoma
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation.
Esophageal Squamous Cell Carcinoma
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Identification and characterization of JMJD2 family genes in silico.
Esophageal Squamous Cell Carcinoma
Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line.
Fibroadenoma
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Gastrointestinal Stromal Tumors
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Gastrointestinal Stromal Tumors
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Glioblastoma
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Glioblastoma
MicroRNA?3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.
Glioblastoma
Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
Glioblastoma
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Glioblastoma
Wnt-Induced Stabilization of KDM4C Is Required for Wnt/?-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.
Glioma
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Glioma
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
Glioma
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Glioma
The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling.
Glomerulonephritis
MicroRNA-340-5p inhibits endothelial apoptosis, inflammatory response, and pro-coagulation by targeting KDM4C in anti-neutrophil cytoplasmic antibody (ANCA)-mediated glomerulonephritis through activation of B cells.
Hemangiosarcoma
KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
Hematologic Neoplasms
Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines.
Hematologic Neoplasms
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Hepatitis B
Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx.
Herpes Simplex
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Herpes Simplex
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Herpesviridae Infections
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Hodgkin Disease
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
Hypersensitivity
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Infarction, Middle Cerebral Artery
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Infections
BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors.
Infections
Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
Infections
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Infections
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
Infections
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Insulin Resistance
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.
Intellectual Disability
A KDM5-Prospero transcriptional axis functions during early neurodevelopment to regulate mushroom body formation.
Intellectual Disability
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Intellectual Disability
Caregiver-reported characteristics of children diagnosed with pathogenic variants in KDM5C.
Intellectual Disability
Heterozygous Variants in KDM4B Lead to Global Developmental Delay and Neuroanatomical Defects.
Intellectual Disability
Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements.
Intellectual Disability
PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an N{varepsilon}-dimethyl lysine demethylase.
Intellectual Disability
Positional cloning and comprehensive mutation analysis identified a novel KDM2B mutation in a Japanese family with minor malformations, intellectual disability, and schizophrenia.
Intellectual Disability
The histone demethylase KDM5 is required for synaptic structure and function at the Drosophila neuromuscular junction.
Ischemic Stroke
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Latent Autoimmune Diabetes in Adults
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Leukemia
A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival.
Leukemia
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Leukemia
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Leukemia
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Leukemia
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
Leukemia
Report of the First Clinical Case of a Moroccan Kabuki Patient with a Novel MLL2 Mutation.
Leukemia
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Leukemia
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Leukemia, Myeloid
Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines.
Leukemia, Myeloid, Acute
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
Leukemia, Myeloid, Acute
KDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p/CCND2 axis through MALAT1.
Leukemia, Myeloid, Acute
Overexpression of KDM4D promotes acute myeloid leukemia cell development by activating MCL-1.
Leukemia, Myeloid, Acute
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Liver Neoplasms
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
Liver Neoplasms
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Lung Neoplasms
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Lung Neoplasms
CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer.
Lung Neoplasms
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Lung Neoplasms
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Lung Neoplasms
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
Lung Neoplasms
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Lung Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Lung Neoplasms
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
Lung Neoplasms
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
Lung Neoplasms
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
Lung Neoplasms
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
Lung Neoplasms
KLF8 overexpression promotes the growth of human lung cancer cells by promoting the expression of JMJD2A.
Lung Neoplasms
MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1? axis.
Lung Neoplasms
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Lung Neoplasms
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Lymphatic Metastasis
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Lymphatic Metastasis
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Lymphatic Metastasis
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Lymphatic Metastasis
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Lymphoma
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Lymphoma, B-Cell
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Lymphoma, B-Cell
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lymphoma, Large B-Cell, Diffuse
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Macular Degeneration
Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells.
Memory Disorders
Increase in GFAP-positive astrocytes in histone demethylase GASC1/KDM4C/JMJD2C hypomorphic mutant mice.
Mesothelioma
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Mesothelioma, Malignant
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Mouth Neoplasms
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Multiple Myeloma
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Multiple Myeloma
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Myocardial Infarction
MiR-134-5p Regulates Myocardial Apoptosis and Angiogenesis by Directly Targeting KDM2A After Myocardial Infarction.
Nasopharyngeal Carcinoma
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Nasopharyngeal Carcinoma
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
Neoplasm Metastasis
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Neoplasm Metastasis
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Neoplasm Metastasis
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Neoplasm Metastasis
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Neoplasm Metastasis
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Neoplasm Metastasis
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Neoplasm Metastasis
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
Neoplasm Metastasis
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
Neoplasm Metastasis
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
Neoplasm Metastasis
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
Neoplasm Metastasis
KDM3A is not associated with metastasis and prognosis of breast cancer.
Neoplasm Metastasis
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Neoplasm Metastasis
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
Neoplasm Metastasis
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
Neoplasm Metastasis
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
Neoplasm Metastasis
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Neoplasm Metastasis
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Neoplasm Metastasis
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Neoplasm Metastasis
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Neoplasm Metastasis
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Neoplasm Metastasis
Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
Neoplasms
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Neoplasms
A Lysine (K)-specific demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
Neoplasms
A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36.
Neoplasms
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin.
Neoplasms
A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.
Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Neoplasms
ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.
Neoplasms
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Neoplasms
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Neoplasms
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Neoplasms
Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
Neoplasms
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Neoplasms
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Neoplasms
Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design.
Neoplasms
CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines.
Neoplasms
Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.
Neoplasms
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Neoplasms
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Neoplasms
Discovery of JMJD7 inhibitors with the aid of virtual screening and bioactivity evaluation.
Neoplasms
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
Neoplasms
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Neoplasms
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Neoplasms
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
Neoplasms
Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Neoplasms
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
Neoplasms
Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B.
Neoplasms
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Neoplasms
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Neoplasms
Expression pattern and regulatory effect of lysine-specific demethylase 2A gene in clear cell renal cell carcinoma.
Neoplasms
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Neoplasms
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Neoplasms
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Neoplasms
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Neoplasms
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project.
Neoplasms
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array.
Neoplasms
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Neoplasms
Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase.
Neoplasms
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Neoplasms
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Neoplasms
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Neoplasms
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Neoplasms
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Neoplasms
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Neoplasms
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Neoplasms
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Neoplasms
Histone demethylase KDM4C activates HIF1?/VEGFA signaling through the costimulatory factor STAT3 in NSCLC.
Neoplasms
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Neoplasms
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
Neoplasms
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Neoplasms
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
Neoplasms
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Neoplasms
HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway.
Neoplasms
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Neoplasms
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Neoplasms
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
Neoplasms
Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucoyl Spermidine.
Neoplasms
Identification of hub genes and key pathways associated with the progression of gynecological cancer.
Neoplasms
IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells.
Neoplasms
In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Neoplasms
Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.
Neoplasms
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
Neoplasms
Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Neoplasms
Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.
Neoplasms
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Neoplasms
iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma.
Neoplasms
JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells.
Neoplasms
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Neoplasms
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
Neoplasms
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
Neoplasms
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
Neoplasms
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
Neoplasms
JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1?-mediated glucose metabolism.
Neoplasms
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Neoplasms
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.
Neoplasms
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Neoplasms
KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.
Neoplasms
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
Neoplasms
KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
Neoplasms
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Neoplasms
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
Neoplasms
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
Neoplasms
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
Neoplasms
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
Neoplasms
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Neoplasms
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
Neoplasms
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
Neoplasms
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Neoplasms
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Neoplasms
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Neoplasms
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
Neoplasms
KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.
Neoplasms
KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation.
Neoplasms
Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation.
Neoplasms
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Neoplasms
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Neoplasms
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Neoplasms
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Neoplasms
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
Neoplasms
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
Neoplasms
Molecular characterization of the porcine JHDM1A gene associated with average daily gain: evaluation its role in skeletal muscle development and growth.
Neoplasms
Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth.
Neoplasms
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Neoplasms
Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype.
Neoplasms
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Neoplasms
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Neoplasms
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing.
Neoplasms
RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A.
Neoplasms
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Neoplasms
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Neoplasms
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Neoplasms
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Neoplasms
Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells.
Neoplasms
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Neoplasms
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Neoplasms
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
Neoplasms
SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.
Neoplasms
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Neoplasms
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Neoplasms
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Neoplasms
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
Neoplasms
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
Neoplasms
The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
Neoplasms
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Neoplasms
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
Neoplasms
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.
Neoplasms
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Neoplasms
The Lysine Demethylase dKDM2 Is Non-essential for Viability, but Regulates Circadian Rhythms in Drosophila.
Neoplasms
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.
Neoplasms
The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments.
Neoplasms
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Neoplasms
The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway.
Neoplasms
Transcription analysis of a histones modifiers panel coupled with critical tumor suppressor genes displayed frequent changes in patients with AML.: mRNA levels of histones modifiers and TSGs in AML.
Neoplasms
Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Neoplasms
ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Neuralgia
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Neuroblastoma
KDM2B regulates choline kinase expression and neuronal differentiation of neuroblastoma cells.
Neuroblastoma
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Neurofibrosarcoma
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Obesity
Correction for Cheng et al., KDM4B protects against obesity and metabolic dysfunction.
Obesity
JMJD2B/KDM4B inactivation in adipose tissues accelerates obesity and systemic metabolic abnormalities.
Obesity
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.
Obesity
KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation.
Osteoarthritis, Knee
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Osteoporosis
Extracellular Vesicle-Encapsulated miR-29b-3p Released From Bone Marrow-Derived Mesenchymal Stem Cells Underpins Osteogenic Differentiation.
Osteoporosis
Histone demethylase KDM4A regulates adipogenic and osteogenic differentiation via epigenetic regulation of C/EBP? and canonical Wnt signaling.
Osteoporosis
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Osteoporosis
Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging.
Osteoporosis
The KDM4B-CCAR1-MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis.
Ovarian Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Ovarian Neoplasms
Histone Demethylase KDM4C Is Required for Ovarian Cancer Stem Cell Maintenance.
Ovarian Neoplasms
IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells.
Ovarian Neoplasms
Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Ovarian Neoplasms
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Ovarian Neoplasms
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ovarian Neoplasms
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Pancreatic Neoplasms
KDM2B is involved in the epigenetic regulation of TGF-?-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
Pancreatic Neoplasms
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
Pancreatic Neoplasms
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
Pituitary Neoplasms
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.
Prostatic Intraepithelial Neoplasia
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Prostatic Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Prostatic Neoplasms
Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
Prostatic Neoplasms
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.
Prostatic Neoplasms
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Prostatic Neoplasms
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Prostatic Neoplasms
Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Prostatic Neoplasms
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Prostatic Neoplasms
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
Prostatic Neoplasms
KDM3A is not associated with metastasis and prognosis of breast cancer.
Prostatic Neoplasms
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
Prostatic Neoplasms
KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
Prostatic Neoplasms
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
Prostatic Neoplasms
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Prostatic Neoplasms
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Prostatic Neoplasms
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Prostatic Neoplasms
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
Prostatic Neoplasms
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
Prostatic Neoplasms
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Prostatic Neoplasms
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Prostatic Neoplasms
Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
Prostatic Neoplasms
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.
Retinoblastoma
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
Rhabdomyosarcoma
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma, Ewing
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Small Cell Lung Carcinoma
Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines.
Spinal Cord Injuries
MicroRNA-137-mediated lysine demethylase 4A regulates the recovery of spinal cord injury via the SFRP4-Wnt/?-Catenin axis.
Squamous Cell Carcinoma of Head and Neck
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Squamous Cell Carcinoma of Head and Neck
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Squamous Cell Carcinoma of Head and Neck
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Starvation
A CxxC Domain That Binds to Unmethylated CpG Is Required for KDM2A to Control rDNA Transcription.
Starvation
CxxC-ZF Domain Is Needed for KDM2A to Demethylate Histone in rDNA Promoter in Response to Starvation.
Starvation
JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation.
Starvation
KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells.
Starvation
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
Starvation
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Stomach Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Stomach Neoplasms
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
Stomach Neoplasms
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
Stomach Neoplasms
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
Stomach Neoplasms
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
Stomach Neoplasms
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
Stomach Neoplasms
LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer.
Stomach Neoplasms
Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.
Stomach Neoplasms
MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B.
Stomach Neoplasms
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Systemic Vasculitis
Correction: Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.
Teratocarcinoma
LSD1 demethylase and the methyl-binding protein PHF20L1 prevent SET7 methyltransferase-dependent proteolysis of the stem-cell protein SOX2.
Tongue Neoplasms
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Triple Negative Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Triple Negative Breast Neoplasms
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Triple Negative Breast Neoplasms
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Urinary Bladder Neoplasms
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Urinary Bladder Neoplasms
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Urinary Bladder Neoplasms
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Urinary Bladder Neoplasms
Tumor?infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Urinary Bladder Neoplasms
Upregulation of JMJD2A promotes migration and invasion in bladder cancer through regulation of SLUG.
Uterine Cervical Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Uterine Cervical Neoplasms
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Uterine Cervical Neoplasms
HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway.
Uterine Cervical Neoplasms
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
Uterine Cervical Neoplasms
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Virus Diseases
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
[histone h3]-dimethyl-l-lysine36 demethylase deficiency
Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate.
[histone h3]-dimethyl-l-lysine36 demethylase deficiency
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). RPH1_YEAST
Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
796
0
90211
Swiss-Prot
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
EXTERNAL LINKS (specific for EC-Number 1.14.11.27)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
